Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jan 3, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Platelet GPVI: a target for antithrombotic therapy?!

Sebastian Dütting¹, Markus Bender, Bernhard Nieswandt

¹University Hospital and Rudolf Virchow Center, DFG-Research Center for Experimental Biomedicine, University of Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.

Trends in Pharmacological Sciences

|August 21, 2012

Summary

Targeting glycoprotein VI (GPVI) offers a novel approach to inhibit platelet activation in cardiovascular and cerebrovascular diseases. Anti-GPVI agents show promise for treating thrombosis without impairing hemostasis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Partial downregulation of platelet glycoprotein VI by low affinity antibodies confers sustained and safe antithrombotic protection.

Signal transduction and targeted therapy·2026

Same author

Comparing anti-platelet and anti-thrombin therapies in the ischaemia-reperfusion injured coronary microcirculation of healthy and diabetic mice.

Basic research in cardiology·2026

Same author

Platelets accelerate endoplasmic reticulum stress and promote hepatic steatosis.

JHEP reports : innovation in hepatology·2026

Same author

European Research Council-funded grant: drivers of thrombo-inflammation.

European heart journal·2026

Same author

The fibrinogen αC region promotes arterial thrombosis in the context of hypofibrinogenemia.

Blood·2026

Same author

Regulation of platelet contractility by agonists present across a thrombus.

Blood advances·2026

Area of Science:

Cardiovascular Research
Hematology
Pharmacology

Background:

Platelet activation is central to ischemic heart and brain diseases.
Current antiplatelet drugs have hemostasis-related limitations.
Glycoprotein VI (GPVI) is a key platelet collagen receptor.

Purpose of the Study:

To review recent advances in understanding GPVI function.
To discuss the therapeutic potential of anti-GPVI agents.
To explore GPVI as a target for treating thrombotic diseases.

Main Methods:

Literature review of GPVI research.
Analysis of GPVI's role in thrombosis and hemostasis.
Discussion of clinical implications of GPVI inhibition.

More Related Videos

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Experiment Videos

Last Updated: Jan 3, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Main Results:

GPVI blockade effectively inhibits experimental thrombosis.
Anti-GPVI strategies do not compromise hemostatic plug formation.
GPVI is a promising target for antithrombotic therapy.

Conclusions:

GPVI inhibition represents a novel therapeutic strategy for ischemic diseases.
Targeting GPVI may offer an improved safety profile over existing antiplatelet drugs.
Further research into anti-GPVI agents is warranted for human pathologies.